Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 189 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: COMBO Clear all
Recruiting Phase 2 Interventional

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

NCT07697456
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Risankizumab, Trosunilimab, ABBV-701
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
61
States / cities
Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Anesthetic Efficacy of 3% Mepivacaine Plus 2% Lidocaine With 1:100,000 Epinephrine for Lower Jaw Dental Injections

NCT01574807
View directory record Official record
Conditions
Pain
Interventions
mepivacaine + lidocaine followed by lidocaine +lidocaine, lidocaine + lidocaine followed by mepivacaine + lidocaine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 22, 2026, 8:24 AM EDT
Completed No phase listed Observational

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

NCT04132557
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
430,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

NCT01644188
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Ezetimibe, Placebo (for ezetimibe), Lipid Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 22, 2026, 8:24 AM EDT
Terminated Phase 1 Interventional

Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer

NCT00958022
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
LBH589 and carboplatin with etoposide
Drug
Lead sponsor
Ahmad Tarhini
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

NCT01909453
View directory record Official record
Conditions
Melanoma
Interventions
LGX818, MEK162, vemurafenib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Identigene STD Test Collection Kit Validation Study

NCT01471392
View directory record Official record
Conditions
Infection
Interventions
STD Diagnostic Kit (Identigene)
Device
Lead sponsor
Identigene
Industry
Eligibility
14 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 22, 2026, 8:24 AM EDT
Terminated Phase 3 Interventional

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

NCT05065411
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
30
States / cities
Chandler, Arizona • Gilbert, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins

NCT00995670
View directory record Official record
Conditions
Hyperglycemia
Interventions
5% dextrose, Vitamin C, Simvastatin, Sevoflurane
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer

NCT00672295
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Dasatinib, Paclitaxel, and Carboplatin
Drug
Lead sponsor
AA Secord
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Tampa, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Black Bean Pasta Consumption on Biomarkers in Young Adults

NCT05182190
View directory record Official record
Conditions
Glucose, High Blood
Interventions
White bread, Black beans whole boiled, Knife Mill pasta, Combo Flour Pasta, Cyclone Flour Pasta
Dietary Supplement
Lead sponsor
Iowa State University
Other
Eligibility
21 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

NCT00412412
View directory record Official record
Conditions
Breast Cancer
Interventions
CNF2024, CNF2024 + trastuzumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Tampa, Florida • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 22, 2026, 8:24 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT03736967
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
REGN3500, Dupilumab, REGN3500 + Dupilumab Combo, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

Study of the Glutaminase Inhibitor CB-839 in Leukemia

NCT02071927
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL)
Interventions
CB-839, CB-Aza
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 22, 2026, 8:24 AM EDT
Terminated Phase 2 Interventional Results available

S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer

NCT00109850
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cetuximab, cisplatin, irinotecan hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
132
States / cities
Mobile, Alabama • Little Rock, Arkansas • Berkeley, California + 84 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

NCT01114282
View directory record Official record
Conditions
Multiple Myeloma
Interventions
velcade, Pralatrexate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

Combining Mechanisms for Better Outcomes (COMBO)

NCT03689920
View directory record Official record
Conditions
Chronic Pain, Back Pain
Interventions
Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
22 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Phoenix, Arizona • La Jolla, California • Greenwood Village, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

Mechanisms for Alcohol Treatment Change [MATCH] Study

NCT02918565
View directory record Official record
Conditions
Alcohol Consumption
Interventions
Drinking Cognition Feedback (DCF), Alcohol Risk Feedback (ARF), Adaptive Goal Support (AGS), COMBO
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 25 Years
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment

NCT00090103
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
dutasteride 0.5mg once daily for 4 years, tamsulosin 0.4mg once daily for 4 years
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older · Male only
Enrollment
4,844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
113
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hoover, Alabama + 98 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 22, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease

NCT03618641
View directory record Official record
Conditions
Melanoma, Lymph Node Cancer
Interventions
CMP-001, Nivolumab
Drug · Biological
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 22, 2026, 8:24 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

NCT06548230
View directory record Official record
Conditions
Myelodysplastic Syndrome(MDS), Acute Myelogenous Leukemia (AML)
Interventions
Nadunolimab, Azacitidine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Terminated Not applicable Interventional Results available

A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders

NCT04247100
View directory record Official record
Conditions
Functional Gastrointestinal Disorders, Vagus Nerve Autonomic Disorder, Irritable Bowel Syndrome, Nausea, Dyspepsia
Interventions
Transcutaneous Electrical Nerve Stimulation (TENS), Sham Transcutaneous Electrical Nerve Stimulation
Device
Lead sponsor
Gisela Grotewold Chelimsky
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 22, 2026, 8:24 AM EDT
Recruiting Phase 1 Interventional

Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

NCT07130695
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Olutasidenib Investigational Agent Administration
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 22, 2026, 8:24 AM EDT
Terminated Phase 3 Interventional

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00662740
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium/Salmeterol QD, Placebo, Salmeterol, Tiotropium/Salmeterol QD+ Salmeterol, Tiotropium (Spiriva®)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
20
States / cities
Boulder, Colorado • Wheat Ridge, Colorado • Winter Park, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 22, 2026, 8:24 AM EDT